Axsome Therapeutics Inc
AXSM152.650USD
+5.650+3.84%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
7.68BMarket Cap
LossP/E TTM
More Details of Axsome Therapeutics Inc Company
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Axsome Therapeutics Inc Info
Ticker SymbolAXSM
Company nameAxsome Therapeutics Inc
IPO dateNov 19, 2015
CEOTabuteau (Herriot)
Number of employees683
Security typeOrdinary Share
Fiscal year-endNov 19
AddressOne World Trade Center, 29Th Floor
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10007
Phone12123323241
Websitehttps://www.axsome.com/
Ticker SymbolAXSM
IPO dateNov 19, 2015
CEOTabuteau (Herriot)
Company Executives of Axsome Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-18.97%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-100.00%
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
57.51K
-18.97%
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
--
-100.00%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
Auvelitv
119.64M
80.32%
Sunosi
28.91M
19.41%
Sunosi royality revenue
1.08M
0.73%
Sunosi License revenue
410.00K
0.28%
By RegionUSD
Name
Revenue
Proportion
United States
146.45M
98.31%
Outside of the United States
2.51M
1.69%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Auvelitv
119.64M
80.32%
Sunosi
28.91M
19.41%
Sunosi royality revenue
1.08M
0.73%
Sunosi License revenue
410.00K
0.28%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Other
66.13%
Shareholders
Shareholders
Proportion
Antecip Capital, L.L.C.
14.57%
The Vanguard Group, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
6.16%
Wellington Management Company, LLP
2.65%
RTW Investments L.P.
2.22%
Other
66.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.04%
Investment Advisor/Hedge Fund
21.86%
Corporation
14.57%
Hedge Fund
11.48%
Research Firm
2.23%
Private Equity
1.35%
Individual Investor
1.13%
Pension Fund
1.11%
Sovereign Wealth Fund
0.93%
Other
9.30%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
643
38.50M
85.28%
+81.77K
2025Q3
657
38.45M
87.16%
-264.98K
2025Q2
636
38.74M
85.21%
+673.17K
2025Q1
604
38.08M
85.89%
-4.20M
2024Q4
561
37.78M
89.40%
-1.53M
2024Q3
529
39.25M
94.83%
-2.09M
2024Q2
515
41.51M
92.29%
+1.90M
2024Q1
502
39.61M
93.44%
-4.74M
2023Q4
476
39.34M
91.45%
+441.54K
2023Q3
467
38.94M
87.84%
+1.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Antecip Capital, L.L.C.
7.34M
14.72%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.94M
7.89%
+67.64K
+1.75%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.14M
6.3%
+173.97K
+5.86%
Jun 30, 2025
Wellington Management Company, LLP
725.04K
1.45%
+21.77K
+3.09%
Jun 30, 2025
RTW Investments L.P.
1.52M
3.04%
-1.41M
-48.10%
Jun 30, 2025
Nomura Investment Management Business Trust
1.14M
2.28%
+161.49K
+16.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
989.45K
1.98%
+54.60K
+5.84%
Jun 30, 2025
T. Rowe Price Associates, Inc.
575.94K
1.15%
+546.97K
+1888.32%
Jun 30, 2025
Invesco Advisers, Inc.
528.53K
1.06%
-217.30K
-29.14%
Jun 30, 2025
State Street Investment Management (US)
958.50K
1.92%
+52.48K
+5.79%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.69%
ALPS Medical Breakthroughs ETF
2.85%
State Street SPDR S&P Pharmaceuticals ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.73%
iShares U.S. Pharmaceuticals ETF
2.09%
Virtus LifeSci Biotech Products ETF
2.03%
ProShares Ultra Nasdaq Biotechnology
0.92%
iShares Health Innovation Active ETF
0.89%
JPMorgan Healthcare Leaders ETF
0.8%
VanEck Pharmaceutical ETF
0.75%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.69%
ALPS Medical Breakthroughs ETF
Proportion2.85%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.73%
iShares U.S. Pharmaceuticals ETF
Proportion2.09%
Virtus LifeSci Biotech Products ETF
Proportion2.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.92%
iShares Health Innovation Active ETF
Proportion0.89%
JPMorgan Healthcare Leaders ETF
Proportion0.8%
VanEck Pharmaceutical ETF
Proportion0.75%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Axsome Therapeutics Inc?
The top five shareholders of Axsome Therapeutics Inc are:
Antecip Capital, L.L.C. holds 7.34M shares, accounting for 14.72% of the total shares.
The Vanguard Group, Inc. holds 3.94M shares, accounting for 7.89% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.14M shares, accounting for 6.30% of the total shares.
Wellington Management Company, LLP holds 725.04K shares, accounting for 1.45% of the total shares.
RTW Investments L.P. holds 1.52M shares, accounting for 3.04% of the total shares.
Antecip Capital, L.L.C. holds 7.34M shares, accounting for 14.72% of the total shares.
The Vanguard Group, Inc. holds 3.94M shares, accounting for 7.89% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.14M shares, accounting for 6.30% of the total shares.
Wellington Management Company, LLP holds 725.04K shares, accounting for 1.45% of the total shares.
RTW Investments L.P. holds 1.52M shares, accounting for 3.04% of the total shares.
What are the top three shareholder types of Axsome Therapeutics Inc?
The top three shareholder types of Axsome Therapeutics Inc are:
Antecip Capital, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Antecip Capital, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Axsome Therapeutics Inc (AXSM)?
As of 2025Q4, 643 institutions hold shares of Axsome Therapeutics Inc, with a combined market value of approximately 38.50M, accounting for 85.28% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.88%.
What is the biggest source of revenue for Axsome Therapeutics Inc?
In FY2025Q2, the Auvelitv business generated the highest revenue for Axsome Therapeutics Inc, amounting to 119.64M and accounting for 80.32% of total revenue.
